Acorda Therapeutics, Inc. Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc.

ACOR

Rangering i aksjer #39162
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Aksjekurs
$0.879
Sist synkronisert: 2024-05-07
Markedsverdi
$582.38K
Endring (1 dag)
9.88%
Endring (1 år)
8,690.00%
Land
US
Handel Acorda Therapeutics, Inc. (ACOR)

Kategori

Healthcare
Historikk for aksjesplitt for Acorda Therapeutics, Inc. (ACOR)
Aksjen Acorda Therapeutics, Inc. (symbol: ACOR) har gjennomgått totalt 2 aksjesplitt.
Den nyeste splittelsen skjedde Jun 05, 2023.
Én ACOR-aksje kjøpt før Jan 04, 2021 tilsvarer i dag 0.0083333333333333 ACOR-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
2023-06-05 1:20 x0.05 x0.0083333333333333
2021-01-04 1:6 x0.16666666666667 x0.16666666666667
Aksjesplitt for lignende selskaper eller konkurrenter